An interventional study of Andy's Mind and Conventional group psychoeducation in Schizophrenia Spectrum and Other Psychotic Disorders, SCHIZOPHRENIA 1 (Disorder) and Schizoaffective Disorder, sponsored by Fundació Sant Joan de Déu. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Fundació Sant Joan de Déu · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Psychotic Disorders with a site in Spain — 15 open to participants now, 19 under way, 4 of them phase 3. Psychotic Disorders · Spain.
Among the 65 studies in Psychotic Disorders with a site in Spain, this one is the 34th largest by planned enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2026, is one of 23 with no phase, reaches primary completion later than 13 of the 18 other live ones, and was the 65th registered.
1,591 studies on the registry are indexed under Psychotic Disorders; 282 are open to participants now.
Browse Psychotic Disorders studies →15 of the 65 studies in Psychotic Disorders with a site in Spain are open now. Recruiting first, the newest first:
University of Oxford · Sites in Spain, Austria, Germany and 6 more countries
Ages 16–40
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Spain, United States, Argentina and 22 more countries
Ages 55–90
Fundació Sant Joan de Déu · Sites in Spain
Ages 18–40
Intra-Cellular Therapies, Inc. · Sites in Spain, United States, Bulgaria and 7 more countries
Ages 55+
Dr. Inge Winter · Sites in Spain, Austria, Germany and 2 more countries
Ages 18–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 205 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 143 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 9 · Phase 4 11
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 65 across 1,324 interventional studies indexed under Psychotic Disorders.
Median enrollment 160 across the 49 interventional studies, 200 across the 15 observational. Of the 29 that completed or were terminated, 8 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 65 have an industry lead sponsor. The 10 most frequent:
Fundació Sant Joan de Déu is the lead sponsor of 72 studies on the registry; 21 are open to participants now.
Fundació Sant Joan de Déu has 9 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Psychotic Disorders with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT05905003Brigham and Women's HospitalAMP SCZ® Observational Study: PREDICT-DPACC | 2027-04-30 |
| NCT07946523Fundació Sant Joan de DéuAndy's Mind: A Co-created Serious Game for People With Psychosis (PSICOGAME) | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies in Psychotic Disorders with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether Andy's Mind, a psychoeducational card game co-created with a person with lived experience of psychosis, improves illness awareness (insight) and attitudes toward treatment in adults with schizophrenia spectrum and other psychotic disorders, compared with conventional group psychoeducation.
The main questions it aims to answer are:
Researchers will also look at psychotic symptoms, attitudes toward alcohol and other drugs, and participant satisfaction.
Participants will:
The study takes place in mental health services in Catalonia, Spain, including prison mental health units, psychosocial rehabilitation services and community mental health centers.
Background Poor insight and low adherence to antipsychotic treatment are common in people with psychotic disorders and are associated with relapse and rehospitalization. Group psychoeducation is an evidence-based intervention that improves illness awareness and adherence, but many patients have difficulty understanding and integrating the information delivered in conventional formats, particularly in settings with cognitive, language and cultural barriers such as prison mental health units. Serious games may increase intrinsic motivation, participation and peer interaction, and reduce the hierarchical structure of conventional psychoeducation. To date, no analog serious game for psychoeducation in psychosis has been evaluated in a randomized controlled trial.
Intervention development The study has two phases. In Phase 1, Andy's Mind was developed through participatory co-design with mental health professionals and a person with lived experience of psychosis, who also illustrated the cards, and was tested in a usability pilot in two prison mental health units (n=10). Phase 1 participants are not eligible for Phase 2. This registration corresponds to Phase 2, the randomized controlled trial.
Experimental intervention Andy's Mind is an analog card game for 2 to 6 players. It uses a science-fiction narrative in which psychotic symptoms are represented as creatures that players learn to stabilize using treatment and protective factors while facing relapse risks such as substance use or sleep deprivation. The final version includes 104 cards in seven categories (symptom, treatment, side effect, protection, attack/relapse, boom and wild cards), with images and text in Spanish, English and Arabic and high-contrast color coding. The intervention consists of 8 weekly group sessions of 45 minutes with 4 to 6 participants: sessions 1 and 2 introduce the rules and the meaning of each card, and sessions 3 to 8 consist of gameplay followed by 5 to 10 minutes of questions to check understanding. Sessions are led by mental health professionals trained by the research team using a facilitator manual.
Active comparator Conventional group psychoeducation based on the PIENSA program, with the same dose (8 weekly sessions of 45 minutes, groups of 4 to 8 participants) and the same content: what psychosis is (session 1), symptoms (sessions 2 and 3), treatments (session 4), side effects (session 5), drugs and psychosis (session 6), relapse prevention, protective and precipitating factors (session 7), and review (session 8).
Design and randomization Multicenter, two-arm, parallel-group, open-label randomized controlled trial. Eighty participants (40 per arm) are recruited by consecutive sampling. Allocation follows a randomization sequence generated by a person external to the research team and linked to the consecutive participant code. Assessments are carried out by members of the research team who do not deliver the interventions; assessors are not blinded to group allocation.
Assessments Participants are assessed at baseline (T0), immediately after the 8-session intervention (T1) and at a 2-month follow-up (T2). Cognitive screening with the SCIP-S is performed at baseline only, as an exclusion criterion. Sociodemographic and clinical data, including a descriptive substance use questionnaire, are collected at baseline. Questionnaires are completed on paper or directly in REDCap depending on device availability and unit regulations; paper data are transcribed into REDCap by the principal investigator.
Sample size and analysis With alpha 0.05 (one-sided) and 80% power, 80 participants allow detection of an effect size of Cohen's d = 0.63 in the between-group comparison at T1 using ANCOVA adjusted for baseline scores, assuming a pre-post correlation of 0.2. The main analysis follows the intention-to-treat principle and compares groups at T1 and T2 with ANCOVA adjusted for baseline values. Care setting (prison, community, rehabilitation) will be considered as a covariate. Change over time will also be explored with repeated-measures or linear mixed models including group, time and group-by-time interaction. A per-protocol analysis will be performed as a complementary analysis.
1,591 studies on the registry are indexed under Psychotic Disorders; 282 are open to participants now.
This study's planned enrollment of 80 is above the median of 65 across 1,324 interventional studies indexed under Psychotic Disorders.
Browse Psychotic Disorders studies →Fundació Sant Joan de Déu is the lead sponsor of 72 studies on the registry; 21 are open to participants now.
Compared within Psychotic Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Schizophrenia Spectrum and Other Psychotic Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants attend 8 weekly group sessions of 45 minutes (4 to 6 participants per group) using the Andy's Mind psychoeducational card game, led by trained mental health professionals.
Behavioral: Andy's Mind
Participants attend 8 weekly group sessions of 45 minutes (4 to 8 participants per group) of conventional psychoeducation based on the PIENSA program, covering the same topics as the experimental arm.
Behavioral: Conventional group psychoeducation
Analog psychoeducational card game for 2 to 6 players, co-designed with mental health professionals and a person with lived experience of psychosis. Psychotic symptoms are represented as creatures that players stabilize using treatment and protective factors while facing relapse risks. 104 cards in seven categories (symptom, treatment, side effect, protection, attack/relapse, boom and wild cards), with text in Spanish, English and Arabic. Sessions 1-2: introduction to rules and cards. Sessions 3-8: gameplay followed by 5-10 minutes of questions to check understanding.
Structured group psychoeducation based on the PIENSA program. Session 1: what is psychosis. Sessions 2-3: symptoms. Session 4: treatments. Session 5: side effects. Session 6: drugs and psychosis. Session 7: relapse prevention, protective and precipitating factors. Session 8: review and questions.
Insight into mental disorder (Scale to Assess Unawareness of Mental Disorder, SUMD)
Insight assessed with the Spanish version of the SUMD, a clinician-rated semi-structured interview that evaluates awareness of having a mental disorder, awareness of the effects of medication and awareness of the social consequences of the disorder, plus awareness and attribution of 17 specific symptoms. Items are scored from 1 (aware) to 5 (unaware); higher scores indicate lower insight. Between-group comparison of post-intervention scores adjusted for baseline.
Time frame: Baseline and immediately after the 8-week intervention
Attitudes toward antipsychotic medication as an indicator of treatment adherence (Drug Attitude Inventory, DAI-10)
Self-reported attitudes and beliefs about psychiatric medication assessed with the Spanish version of the 10-item Drug Attitude Inventory (DAI-10). Each item is scored +1 or -1; total score ranges from -10 to +10, with higher scores indicating more positive attitudes toward medication. Between-group comparison of post-intervention scores adjusted for baseline.
Time frame: Baseline and immediately after the 8-week intervention
Maintenance of insight (SUMD) at follow-up
SUMD scores as described for the primary outcome, compared between groups at 2-month follow-up adjusted for baseline. Higher scores indicate lower insight.
Time frame: Baseline and 2 months after the end of the intervention
Maintenance of attitudes toward medication (DAI-10) at follow-up
DAI-10 total score (range -10 to +10; higher scores indicate more positive attitudes toward medication), compared between groups at 2-month follow-up adjusted for baseline.
Time frame: Baseline and 2 months after the end of the intervention
Psychotic symptom severity (Positive and Negative Syndrome Scale, PANSS)
Clinician-rated severity of positive, negative and general psychopathology symptoms assessed with the 30-item PANSS. Each item is scored from 1 (absent) to 7 (extreme); total score ranges from 30 to 210, with higher scores indicating greater symptom severity. Total and subscale scores will be analyzed.
Time frame: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Attitudes toward alcohol (Escala de Actitudes hacia el Alcohol, ESACAL)
Self-reported attitudes toward alcohol assessed with the 13-item ESACAL, rated on a 5-point Likert scale (total score range 13 to 65). Items unfavorable to health are reverse-scored, so higher scores indicate attitudes more favorable to health.
Time frame: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Attitudes toward other drugs (Escala de Actitudes hacia otras Drogas, ESACDRO)
Self-reported attitudes toward drugs other than alcohol assessed with the 13-item ESACDRO, rated on a 5-point Likert scale (total score range 13 to 65). Items unfavorable to health are reverse-scored, so higher scores indicate attitudes more favorable to health.
Time frame: Baseline, immediately after the 8-week intervention, and 2 months after the end of the intervention
Satisfaction and engagement with the intervention
Self-reported satisfaction and engagement with the intervention assessed with an ad hoc questionnaire rated on a 5-point Likert scale (1 to 5), with higher scores indicating greater satisfaction. Compared between groups.
Time frame: Immediately after the 8-week intervention
Plan to share: Yes — De-identified individual participant data underlying the results reported in publications (sociodemographic variables and SUMD, DAI-10, PANSS, ESACAL, ESACDRO and satisfaction scores) will be available upon reasonable request. Because the sample includes people in prison mental health settings, a vulnerable population, data will not be deposited in an open repository and will only be shared under a data sharing agreement, for purposes consistent with the informed consent.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 6 months after publication of the main results and for 5 years thereafter.
Access criteria: Researchers who provide a methodologically sound proposal approved by an ethics committee may request access by contacting the principal investigator. Access requires approval by the sponsor (Fundació per a la Recerca i la Docència Sant Joan de Déu) and the signing of a data sharing agreement in compliance with the EU General Data Protection Regulation.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.
Of 459 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 19 months is below that.
Counting every sponsor, half of 461 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Sant Joan de Déu